| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.0035 | 1 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.0029 | 1 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.0089 | 1 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |